Role of Epithelial to Mesenchymal Transition in Colorectal Cancer.
CMS
CRC
CSC
CTC
EMP
EMT
EMT-TF
MET
TGF-β
TME
biomarkers
clinical prognosis
tumor heterogeneity
tumor microenvironment
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
04
09
2023
revised:
28
09
2023
accepted:
29
09
2023
medline:
1
11
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
The epithelial-mesenchymal transition (EMT) is a cellular reprogramming process that occurs during embryonic development and adult tissue homeostasis. This process involves epithelial cells acquiring a mesenchymal phenotype. Through EMT, cancer cells acquire properties associated with a more aggressive phenotype. EMT and its opposite, mesenchymal-epithelial transition (MET), have been described in more tumors over the past ten years, including colorectal cancer (CRC). When EMT is activated, the expression of the epithelial marker E-cadherin is decreased and the expression of the mesenchymal marker vimentin is raised. As a result, cells temporarily take on a mesenchymal phenotype, becoming motile and promoting the spread of tumor cells. Epithelial-mesenchymal plasticity (EMP) has become a hot issue in CRC because strong inducers of EMT (such as transforming growth factor β, TGF-β) can initiate EMT and regulate metastasis, microenvironment, and immune system resistance in CRC. In this review, we take into account the significance of EMT-MET in CRC and the impact of the epithelial cells' plasticity on the prognosis of CRC. The analysis of connection between EMT and colorectal cancer stem cells (CCSCs) will help to further clarify the current meager understandings of EMT. Recent advances affecting important EMT transcription factors and EMT and CCSCs are highlighted. We come to the conclusion that the regulatory network for EMT in CRC is complicated, with a great deal of crosstalk and alternate paths. More thorough research is required to more effectively connect the clinical management of CRC with biomarkers and targeted treatments associated with EMT.
Identifiants
pubmed: 37834263
pii: ijms241914815
doi: 10.3390/ijms241914815
pmc: PMC10573312
pii:
doi:
Substances chimiques
Cadherins
0
Transcription Factors
0
Transforming Growth Factor beta
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : China Scholarship Council
ID : CSC 201906090390
Organisme : Ulm University
ID : L.SBN 0220
Références
Semin Cancer Biol. 2012 Oct;22(5-6):455-61
pubmed: 22627188
Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):521-531
pubmed: 35505243
Annu Rev Pathol. 2017 Jan 24;12:331-357
pubmed: 27959637
Theranostics. 2022 Jul 4;12(11):5138-5154
pubmed: 35836817
Dev Cell. 2019 May 6;49(3):313-316
pubmed: 31063750
Trends Cancer. 2016 Sep;2(9):495-504
pubmed: 28741478
Genome Med. 2021 Sep 1;13(1):143
pubmed: 34470666
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Nat Rev Dis Primers. 2023 Apr 27;9(1):22
pubmed: 37105965
Clin Cancer Res. 2017 Dec 1;23(23):7209-7216
pubmed: 28939741
Mol Cancer. 2022 Apr 23;21(1):104
pubmed: 35461253
Cell Oncol (Dordr). 2019 Aug;42(4):405-421
pubmed: 30980365
J Extracell Vesicles. 2022 May;11(5):e12226
pubmed: 35595718
Lancet Oncol. 2021 Jul;22(7):898-899
pubmed: 34048687
Cancer Cell. 2012 Dec 11;22(6):699-701
pubmed: 23238008
J Exp Med. 2019 May 6;216(5):1016-1026
pubmed: 30975895
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):262-274
pubmed: 35090605
Mol Aspects Med. 2014 Oct;39:61-81
pubmed: 23927966
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Dev Cell. 2019 Nov 18;51(4):417-419
pubmed: 31743661
J Biomed Sci. 2018 Jul 19;25(1):57
pubmed: 30025541
Semin Cancer Biol. 2012 Jun;22(3):194-207
pubmed: 22406545
Biomed Pharmacother. 2023 Apr;160:114395
pubmed: 36804124
Nature. 2020 Jan;577(7791):566-571
pubmed: 31915377
Cell Death Dis. 2020 Feb 24;11(2):147
pubmed: 32094334
Oncogene. 2012 Apr 19;31(16):2062-74
pubmed: 21874049
Nat Rev Clin Oncol. 2017 Apr;14(4):235-246
pubmed: 27922044
Semin Cancer Biol. 2023 May;90:15-28
pubmed: 36773819
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Cell Stem Cell. 2014 Dec 4;15(6):692-705
pubmed: 25479747
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188718
pubmed: 35304296
Annu Rev Pathol. 2018 Jan 24;13:395-412
pubmed: 29414248
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):218-229
pubmed: 28174420
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
BMJ. 2021 May 4;373:n877
pubmed: 33947661
Lancet Oncol. 2021 Aug;22(8):e358-e368
pubmed: 34339656
Mol Cancer. 2022 Jul 14;21(1):144
pubmed: 35836256
Gastroenterology. 2022 Jan;162(1):26-31
pubmed: 31254502
Gastroenterology. 2022 Aug;163(2):520-526
pubmed: 35715380
N Engl J Med. 2022 Jun 16;386(24):2330-2331
pubmed: 35657319
Nature. 2017 Mar 29;543(7647):676-680
pubmed: 28358093
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Biochim Biophys Acta Rev Cancer. 2022 Sep;1877(5):188797
pubmed: 36100193
Semin Cancer Biol. 2018 Dec;53:232-247
pubmed: 30130662
Mol Cancer. 2021 Feb 8;20(1):29
pubmed: 33557837
Gastroenterology. 2021 May;160(6):1947-1960
pubmed: 33617889
Gastroenterology. 2022 Sep;163(3):574-576
pubmed: 35809616
Mol Cancer. 2022 Mar 25;21(1):86
pubmed: 35337361
Drug Resist Updat. 2010 Aug-Oct;13(4-5):109-18
pubmed: 20692200
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
CA Cancer J Clin. 2022 Jul;72(4):372-401
pubmed: 35472088
Front Immunol. 2022 Nov 17;13:1057181
pubmed: 36466926
BMJ. 2023 Jan 27;380:200
pubmed: 36707088
Nat Genet. 2020 Jun;52(6):594-603
pubmed: 32451460
Gastroenterology. 2021 Apr;160(5):1584-1598
pubmed: 33385426
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Gastroenterology. 2022 Mar;162(3):715-730.e3
pubmed: 34757143
Mol Cancer. 2019 May 7;18(1):91
pubmed: 31064356
Cancers (Basel). 2017 Dec 16;9(12):
pubmed: 29258163
Int J Mol Sci. 2022 Dec 19;23(24):
pubmed: 36555840
Semin Cancer Biol. 2022 Nov;86(Pt 2):436-449
pubmed: 35700938
Ann Oncol. 2019 Oct 1;30(10):1538-1540
pubmed: 31504141
Annu Rev Pathol. 2023 Jan 24;18:467-492
pubmed: 36323004
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Semin Cancer Biol. 2019 Oct;58:1-10
pubmed: 30453041
Trends Pharmacol Sci. 2023 Apr;44(4):222-236
pubmed: 36828759
Lancet Gastroenterol Hepatol. 2022 Jul;7(7):588-590
pubmed: 35397797
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704
pubmed: 31554963
EMBO Rep. 2008 Jun;9(6):582-9
pubmed: 18483486
Gastroenterology. 2021 Aug;161(2):592-607
pubmed: 33930428
Cancer Res. 2020 Dec 15;80(24):5569-5582
pubmed: 33055221
Nat Cell Biol. 2009 Dec;11(12):1487-95
pubmed: 19935649
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
BMJ. 2021 Sep 15;374:n1855
pubmed: 34526356
Trends Cell Biol. 2020 Oct;30(10):764-776
pubmed: 32800658
Genes Dev. 2021 Jun;35(11-12):787-820
pubmed: 34074695
Nat Rev Drug Discov. 2014 Jul;13(7):497-512
pubmed: 24981363
J Exp Clin Cancer Res. 2022 Mar 8;41(1):86
pubmed: 35260172
Gastroenterology. 2013 Sep;145(3):647-57.e15
pubmed: 23684708
Nat Rev Mol Cell Biol. 2022 Feb;23(2):89-90
pubmed: 34887545
BMJ. 2019 Jun 24;365:l4280
pubmed: 31235545
Nano Lett. 2017 May 10;17(5):3320-3326
pubmed: 28440076
Mol Cancer. 2022 Mar 12;21(1):74
pubmed: 35279145
Nat Genet. 2017 May;49(5):708-718
pubmed: 28319088
Mol Cancer. 2017 Jan 17;16(1):12
pubmed: 28095858
Semin Cancer Biol. 2020 Feb;60:148-156
pubmed: 31521746
Brief Bioinform. 2021 Jul 20;22(4):
pubmed: 33300554
Mol Cancer. 2012 Nov 23;11:87
pubmed: 23174018
Ann Surg. 2020 Jan;271(1):75-85
pubmed: 31188207
Cell. 2021 Dec 22;184(26):6262-6280.e26
pubmed: 34910928
Cancer Res. 2022 Apr 15;82(8):1467-1469
pubmed: 35425957
JAMA Netw Open. 2018 Oct 5;1(6):e183115
pubmed: 30646224
Gastroenterology. 2020 Jan;158(2):291-302
pubmed: 31622622
Gut. 2023 Jun;72(6):1129-1142
pubmed: 35953094
Nat Rev Immunol. 2021 Oct;21(10):653-667
pubmed: 33911231
Int J Cancer. 2020 May 1;146(9):2547-2562
pubmed: 31506938
N Engl J Med. 2022 Aug 25;387(8):759
pubmed: 36001720
CA Cancer J Clin. 2023 May-Jun;73(3):233-254
pubmed: 36856579
N Engl J Med. 2022 Apr 21;386(16):1547-1558
pubmed: 35443109
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):111-130
pubmed: 31900466
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Trends Cell Biol. 2015 Nov;25(11):675-686
pubmed: 26437589
Cancer Res. 2020 Jan 15;80(2):304-318
pubmed: 31732654
JAMA Oncol. 2023 Jun 1;9(6):770-778
pubmed: 37079312
Trends Cancer. 2017 Mar;3(3):166-168
pubmed: 28718430
Mol Cancer. 2016 Dec 3;15(1):77
pubmed: 27912767
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):700
pubmed: 35809603
Cancer Commun (Lond). 2021 Feb;41(2):154-170
pubmed: 33389821
Pharmacol Ther. 2018 Feb;182:80-94
pubmed: 28834698
Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):677-678
pubmed: 34282305
JAMA. 2019 May 28;321(20):2022-2023
pubmed: 31021387
Oncoimmunology. 2021 May 11;10(1):1923910
pubmed: 34026335
Semin Cancer Biol. 2019 Apr;55:37-52
pubmed: 29775690
N Engl J Med. 2020 Aug 27;383(9):871-873
pubmed: 32846069
Nature. 2023 Apr;616(7955):168-175
pubmed: 36949199
Immunity. 2019 Apr 16;50(4):992-1006
pubmed: 30995511
Gut. 2019 Dec;68(12):2129-2141
pubmed: 31366457
Ann Surg. 2022 Nov 1;276(5):897-904
pubmed: 35880752
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Nat Rev Cancer. 2021 May;21(5):325-338
pubmed: 33547455
N Engl J Med. 2017 Aug 31;377(9):888-890
pubmed: 28854096
Semin Cancer Biol. 2022 Sep;84:199-213
pubmed: 33848627
Clin Cancer Res. 2021 Sep 1;27(17):4669-4679
pubmed: 33827891
N Engl J Med. 2022 Oct 27;387(17):1547-1556
pubmed: 36214590
Mol Cancer. 2019 Mar 30;18(1):64
pubmed: 30927925
Cancer Commun (Lond). 2021 Dec;41(12):1275-1313
pubmed: 34791817
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Mol Cancer. 2021 Feb 3;20(1):26
pubmed: 33536039
J Exp Clin Cancer Res. 2022 Sep 16;41(1):278
pubmed: 36114510
Ann Surg. 2014 Apr;259(4):735-43
pubmed: 23982750
Gastroenterology. 2011 Jul;141(1):279-91, 291.e1-5
pubmed: 21640118
J Hematol Oncol. 2022 Sep 8;15(1):129
pubmed: 36076302